Getting Through Vascular Biology Conference 2023 Without Losing Your Mind
The Vascular Biology Conference 2023 was held in Naples, Italy, organized by the American Heart Association. It ran from February 25 through March 1, 2023. If you're looking at the abstract proceedings now, you're probably trying to figure out which talks actually matter for your research or which papers got cited enough to be worth reading. Most of them aren't. I spent three days sitting through sessions on endothelial function, angiogenesis, and vascular calcification. The useful material is there, but it's buried under a lot of incremental work that adds maybe two percentage points to whatever somebody already published in 2019. The keynotes were fine—Richard Cohen from the University of Florida gave a solid talk on shear stress sensing, and Joan Schwartz's retrospective on smooth muscle cell plasticity was one of the better presentations. But the real value for most people is in the poster sessions and the late-breaking clinical data.
Vascular Biology Conference 2023 Key Takeaways
One thing nobody warned me about before attending was how much time you waste deciding whether to stay at a session or leave. There's always overlapping content on adjacent tracks. I ended up switching between microvascular dysfunction talks and thrombosis symposia without finishing either properly. My workaround was simple: I wrote down the session codes on my phone before the conference started, flagged the ones I absolutely needed to attend, and accepted that I'd miss roughly forty percent of what was offered. That's normal. Everybody does it. The abstract download process through the AHA portal was slower than it needed to be. I waited about ten minutes for the full program PDF to render on my laptop. It didn't save well. I ended up screenshots instead, which turned out to be the better option when you're trying to reference specific session times across different days. From a technical standpoint, the most cited work coming out of this conference centered on single-cell RNA sequencing of vascular cells and the role of pericytes in fibrotic remodeling. Both topics have been hot for a while, but the quality of data presented here was genuinely better than previous years. A few groups showed that pericyte heterogeneity is far more pronounced than the textbooks suggest. That's not a new idea, but the single-cell resolution made it harder to ignore.
Another counter-intuitive finding that came up repeatedly was the disconnect between in vivo and in vitro results when studying endothelial-to-mesenchymal transition. Several labs presented data showing that what looks like a clear Edil1-positive transition in culture basically falls apart when you look at lineage-traced models in living tissue. I've seen this pattern before at other meetings, but it came up more at Vascular Biology Conference 2023 than any recent event I've attended. It's worth keeping in mind if you're designing experiments around endMT, because the assay you pick will determine whether you get a positive result or not. The clinical translation angle was weaker than I expected. There were some interesting talks on novel anti-angiogenic strategies for calcific aortic valve disease, but most of them were phase one or two data with small sample sizes. Nothing that would change practice tomorrow. The one exception was a multicenter study on endothelial progenitor cell therapy in critical limb ischemia that showed a statistically significant improvement in wound healing at twelve weeks. The effect size was modest, and the mechanism is still unclear, but it's one of the cleaner positive trials in this space in a while. Networking at these conferences is unavoidable. I tried to skip the social events entirely both years I attended similar meetings, and it didn't work. You end up missing the conversations that actually matter—the ones where somebody mentions they're working on a related problem and you realize you could collaborate instead of duplicating effort. This year I went to one mixer on the third evening. I talked to three people. One of them knew someone who was reviewing a paper I'd submitted earlier that year. Not glamorous, but that's how it works.
Get the Full Details
If you're planning to access the proceedings after the fact, the AHA website hosts the abstracts under the conference archive section. The download is free for members and costs about seventy-five dollars for non-members. The full-text publications from selected sessions eventually show up in circulation research and arteriosclerosis thrombosis and vascular biology, usually within six to eight months. Sometimes they don't. A number of the poster presentations never made it into print, which is frustrating if you heard something specific and can't track it down later. I should mention one practical limitation that caught me off guard. The conference app had real-time session updates, but it crashed twice during the first two days. Both times I missed announcements about room changes. I switched to using the printed program booklet as my primary reference after that. It's an old-school workaround, but it worked reliably for the rest of the conference. For people who can't attend in person, the recorded sessions are available through the AHA digital library for several months after the event. The audio quality on some of the later-day sessions was poor, probably due to the venue's acoustics and the number of people in the room. Video recordings exist but aren't always synced correctly to the slides. If you're watching remotely, you'll want to pull up the PDF abstracts alongside the playback.
The registration cost was around fourteen hundred dollars for early bird and seventeen hundred at the door. Travel to Naples added another eight to twelve hundred depending on where you flew from. If your department has conference funding, it's worth applying to the AHA student travel grants beforehand. They cover up to five hundred dollars and don't require you to present, though having an accepted abstract does help with the review. I don't recommend this conference for people who want hard clinical answers. It's a research conference, and it functions as one. The quality is good, the turnout is solid, and the networking opportunities are decent if you push yourself into them. But if you're looking for practice-changing results, you'll be disappointed. The gap between mouse models and human disease remains wide, and this conference made that clear without pretending otherwise.
